Publications from 2010

First author from Finsen Laboratory

Thurison, T.S., Lomholt, A.F., Rasch, M.G., Lund, I.K., Nielsen, H.J., Christensen, I.J., and Høyer-Hansen, G.:
A new assay for the measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Clin. Chem. 56:1636-1640.

Jögi, A., Rønø, B., Lund, I.K., Nielsen, B.S., Ploug, M., Høyer-Hansen G., Rømer, J., and Lund, L.R.:
Neutralization of uPA with a monoclonal antibody reduce plasmin formation and delays wound healing in tPA-deficient mice.
Plos One, 5:e12746.

Rasch, M.G., Lund, I.K., Illemann, M., Høyer-Hansen, G. and Gårdsvoll, H.:
Purification and characterization of recombinant full-length and protease-domain of murine MMP-9 in Drosophila S2 cells.
Protein Expression and Purification. 72: 87-94

Alpízar-Alpízar, W., Nielsen, B.S., Sierra, R., Illemann, M., Ramı´rez, J.A., Arias, A., Dura´n, S., Skarstein, A., Ovrebo, K., Lund, L.R. and Laerum, O.D.:
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Int. J. Cancer. 126: 405–415.

Frøssing, S., Rønø, B., Hald, A., Rømer, J. and Lund, L.R.:
Skin wound healing in MMP2-deficient and MMP2 ⁄ Plasminogen double-deficient mice.
Experimental Dermatology. 19: e234–e240.

Hald, A., Rønø, B., Melander, M.C., Ding, M., Holck, S. and Lund, L.R.:
MMP9 is protective against lethal inflammatory mass lesions in the mouse colon.
Disease Models & Mechanisms. Epub ahead of print.

Almasi, C.E., Brasso, K., Iversen, P., Pappot, H., Høyer-Hansen, G., Danø, K. and Christensen, I.J.:
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Prostate. Epub ahead of print.


Joint publications with co-author from Finsen Laboratory

Bülow, S., Christensen, I., Iversen, L. and Harling, H.:
Intraoperative perforation is an important predictor of local recurrence and impaired survival after abdominoperineal excision for rectal cancer.
Colorectal Dis. Epub ahead of print.

Petri, A.L., Simonsen, A.H., Høgdall, E., Christensen, I.J., Kjaer, S.K., Yip,C., Risum, S., Pedersen, A.T., Hartwell, D., Fung, E.T. and Høgdall, C.:
Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.
Proteomics. Clin. Appl. 4: 304-314.

Høgdall, E., Fung, E.T., Christensen, I.J., Yip, C., Nedergaard, L., Engelholm, S.A., Risum, S., Petri, A.L., Lundvall, L., Lomas, L. and Høgdall, C.:
Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients.
Proteomics. Clin. Appl. 4: 940-952.

Aldulaymi, B., Christensen, I.J., Soletormos, G., Jess, P., Nielsen, S.E., Laurberg, S., Brunner, N. and Nielsen, H. J.:
Chemoradiation induced Changes in Serum CEA and Plasma TIMP-1 in Patients with Locally Advanced Rectal Cancer.
Anticancer Res. 30:4755-4759.

Svendsen, M.N., Brunner, N., Christensen, I.J., Ytting, H., Bentsen, C., Lomholt, A.F. and Nielsen, H.J.:
Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancerr.
Scand. J. Clin. Lab Invest. 70: 503-511.

Sugiyama, N., Varjosalo, M., Meller, P., Lohi, J., Hyytiäinen, M., Kilpinen, S., Kallioniemi, O., Ingvarsen, S., Engelholm, L.H., Taipale, J., Alitalo, K., Keski-Oja, J. and Lehti, K.:
Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Cancer Res. 70: 7851-61

Kjellman, A., Akre, O., Gustafsson, O., Høyer-Hansen, G., Lilja, H., Norming, U., Piironen, T., Törnblom, M.:
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
J Intern Med. Epub ahead of print.

Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. T., Lassen, U.:
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
APMIS. 118: 585-594.

Høgdall, E. V., Christensen, L., Kjaer, S. K., Blaakaer, J., Christensen, I. J., Høgdall, C. K.:
Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study.
APMIS. 118, 557-564.

Frederiksen, C., Qvortrup, C., Christensen, I. J., Glimelius, B., Berglund, A., Jensen, B. V., Nielsen, S. E., Keldsen, N., Nielsen, H. J., Brunner, N., Pfeiffer, P.:
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Ann. Oncol. Epub ahead of print.

Birgisson, H., Nielsen, H. J., Christensen, I. J., Glimelius, B., Brunner, N.:
Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: A prospective validation study. Eur. J. Cancer. 46: 3323-3331.

Hetland, M. L., Christensen, I. J., Tarp, U., Dreyer, L., Hansen, A., Hansen, I. T., Kollerup, G., Linde, L., Lindegaard, H. M., Poulsen, U. E., Schlemmer, A., Jensen, D. V., Jensen, S., Hostenkamp, G. H., Ostergaard, M.:
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Arthritis Rheum. 62: 22-32.

Klintman, M., Ornbjerg, W. S., Christensen, I. J., Braemer, H. P., Ferno, M., Malmberg, M., Mouridsen, H., Cold, F., Schrohl, A. S., Foekens, J. A., Malmstrom, P., Brunner, N.:
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res. Treat. 121, 365-371.

Lomholt, A.F., Christensen I.J., Høyer-Hansen, G., Nielsen, H.J.: Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Acta Oncol. 49: 805-811.

Grum-Schwensen B, Klingelhöfer J, Grigorian M, Almholt K, Nielsen BS, Lukanidin E, Ambartsumian N.:
Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors.
Cancer Res. 70:936-47.

Thoren LA, Nørgaard GA, Weischenfeldt J, Waage J, Jakobsen JS, Damgaard I, Bergström FC, Blom AM, Borup R, Bisgaard HC, Porse BT.:
UPF2 is a critical regulator of liver development, function and regeneration.
PLoS One. 5:e11650.

Connolly, B. M., E. Y. Choi, H. Gårdsvoll, A. L. Bey, B. M. Currie, T. Chavakis, S. Liu, A. Molinolo, M. Ploug, S. H. Leppla, and T. H. Bugge:
Selective abrogation of uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.
Blood, 116:1593-1603.

Egeblad, M., Rasch, M.G. and Weaver, V.M.:
Dynamic interplay between the collagen scaffold and tumor evolution.
Curr opin cell biol. 22: 697-706.

Lin, L., Gårdsvoll, H., Huai, Q., Huang, M., and Ploug, M.:
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: Implications for preclinical cancer therapy.
J Biol Chem. 285: 10982-10992.

Olson, F.J., Thurison,T., Ryndel, M., Høyer-Hansen, G. and Fagerberg, B.:
The soluble urokinase-type plasminogen activator receptor is associated with cardiovascular disease and risk factors in patients with symptomatic carotid atherosclerosis.
Clin. Biochem. 43:124-130.

Troelsen, L.N., Garred, P., Christiansen, B., Torp-Pedersen, C., Christensen, I.J., Narvestad, E. and Jacobsen, S.:
Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis.
Mol Immunol. 47: 713-718.

Bruyère F, Melen-Lamalle L, Blacher S, Detry B, Masset A, Lecomte J, Lambert V, Maillard C, Høyer-Hansen G, Lund LR, Foidart JM and Noël A:
Does plasminogen activator inhibitor-1 drive lymphangiogenesis?
PLoS One. 5: e9653.

Nielsen HJ, Christensen IJ and Brünner N:
A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
Scand J Gastroenterol. 45: 200-207.

Begum FD, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Christensen L and Høgdall C:
Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Acta Obstet Gynecol Scand. 89:190-198.

Aldulaymi B, Christensen IJ, Sölétormos G, Jess P, Nielsen SE, Brünner N and Nielsen HJ:
Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
Anticancer Res. 30: 233-237.

Knudsen AL, Bülow S, Tomlinson I, Möslein G, Heinimann K and Christensen IJ:
Attenuated Familial Adenomatous Polyposis (AFAP) Results from an international collaborative study.
Colorectal Dis. Epub ahead of print.

Begum FD, Høgdall E, Christensen IJ, Christensen L, Kjaer SK, Blaakaer J, Petri AL and Høgdall C:
Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
Gynecol Oncol. 117:446-450.

Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K and Peterson C:
The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.
Blood. 115: 4671-4677.

Sørensen, K.P., Lutterodt, M.C., Byskov, A.G. and Larsen, J.K.:
Flow cytometric DNA analysis of germ cells and somatic cells in first trimester human embryonic gonads. Possible effect of mother’s smoking.
Human Reproduction. Epub ahead of print.

Gao, S., Nielsen, B.S., Krogdahl, A., Sørensen, J.A., Tagesen, J., Dabelsteen, S., Dabelsteen, E., Andreasen, P.A.:
Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa.
Genes Chromosomes Cancer. 49: 526-538.